patent 2 페이지

본문 바로가기
Home  >  Technology  >  Patents and Publications
  • Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy. J Med Virol. 2013;85(1):55-64.

  • Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. Scand

  • Michailidis E, Singh K, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots. Int J Curr Chem. 2011;2(4):253-260.

  • Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: Focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44(7):1060-1071.

  • Lee HW, Kim HJ, Hong SP, Cha BK, Chang HY, Choi CH, Do JH, Kim JG, Chang SK.Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient. Intervirology. 2012;55(5):380-384.

  • Kim SS, Cheong JY, Lee D, Lee MH, Hong SP, Kim SO, Cho SW. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. J Med Virol. 2012;84(1):18-25

  • Jang JW, Chun JY, Park YM, Shin SK, Yoo W, Kim SO, Hong SP. Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci. 2011;103(2):296-304

  • Hong SP. Monitoring of hepatitis B: Detection of drug resistance. Korean J Hepatol. 2011;17(4S):22-37.

  • Cha YS, Choi SH, Lee JH, Shin SK, Lee SH, Lee SD, Kim SO, Hong SP. Analysis of TPOX short tandem repeat locus with matrix-associated laser desorption/ionization time-of-flight-based restriction fragment mass polymorphism assay. Anal Biochem 2011 ;412(1):7

  • Lee HP, Kim SO, Hwang TS, Bae JM, Kim SN, Kim JW, Hwang SY, Lee HS, Shin SK, Cho W, Hong SP. Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses.

  • Han KH*, Hong SP*, Choi SH, Shin SK, Cho SW, Ahn SH, Hahn JS, Kim SO. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antiviral Therapy 2011;16(1):77-87.

  • Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant

  • Oh YJ, Park YM, Hong SP, Shin SK, Ji SI, Kim BH, Park SJ, Hong Z. A YIDD Mutation in a Case of Recurrent Hepatitis B after Liver Transplantation Induced by an S-escape Mutant. Gut Liver. 2010;4(2):253-7.

  • Kim BU, Goo JC, Park BC, Kim SO, Hong SP, Jeong JI, Chae HB, Park SM, Youn SJ. Genotypic resistance to entecavir in chronic hepatitis B patients. Korean J Hepatol. 2010;16(2):147-57.

  • Song J, Kim OJ, Km HS, Bae SJ, Hong SP, Oh DY, Kim NK. Endothelial nitric oxide synthase gene polymorphisms and the risk of silent brain infarction. Int J Mol Med 2010;25:819-823.

  • Lee JM, Park JY, Lee CK, Kim DY, Nguyen T, Hong SP, Kim SO, Chon JY, Han KH, Ahn SH. Long term adefovir dipivoxil monotherapy for up to 5 years in lamivudine resistant chronic hepatitis B. Antiviral Therapy 2010;15-235-241.

  • Han IB, Kim OJ, Ahn JY, Oh D, Hong SP, Huh R, Chung SS, Kim NK. Association of Methylenetetrahydrofolate Reductase (MTHFR 677C>T and 1298A>C) Polymorphisms and Haplotypes with Silent Brain Infarction and Homocysteine Levels in a Korean Population. Yonsei

  • Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antiviral

  • Lee JM, Kim HJ, Park JY, Lee CK, Kim DY, Kim JK, Lee HW, Pail YH, Lee KS, Han KH, Chon JY, Hong SP, Nguyen T. Rescue Monotherapy in Lamivudine-Resistant HBeAg Positive Chronic Hepatitis B: Adefovir Versus Entecavir. Antiviral Therapy 2009 ;14:705-712.

  • Cho SW, Koh JY, Cheong JY, Lee MH, Hong SP, Yoo W, Kim SO. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepatitis 2010;17:171-177.